USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 12, 2022 (est) | Jun 30, 2022 | - | $-1.55 | $-1.75 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 12, 2022 (est) | Jun 30, 2022 | - | $3.11M | $3.11M |
Aptevo Therapeutics Inc's next estimated earnings date (based on same quarter last year's date) is Aug 12, 2022 for the fiscal quarter ending Jun 30, 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 1 | $-4.23 | $-4.23 | $-4.23 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 2 / 0 | $-5.18 | $-5.18 | $-4.84 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $15.90M | $13.80M | $18.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 12, 2022 | Mar 2022 | $-1.15 | $-1.55 | -34.78% |
| Mar 24, 2022 | Dec 2021 | $-1.29 | $-1.27 | 1.55% |
| Nov 12, 2021 | Sep 2021 | $-1.47 | $-1.43 | 2.72% |
| Aug 12, 2021 | Jun 2021 | $-2.00 | $-1.75 | 12.50% |
| May 11, 2021 | Mar 2021 | $1.69 | $-1.64 | -197.04% |
| Mar 31, 2021 | Dec 2020 | $-1.22 | $-1.92 | -57.38% |
| Nov 10, 2020 | Sep 2020 | $-2.01 | $-2.10 | -4.48% |
| Aug 14, 2020 | Jun 2020 | $-2.06 | $-2.10 | -1.94% |
| May 13, 2020 | Mar 2020 | $-2.35 | $0.89 | 137.87% |
| Mar 25, 2020 | Dec 2019 | $-3.59 | $-2.38 | 33.70% |
| Nov 7, 2019 | Sep 2019 | $-3.36 | $-2.24 | 33.33% |
| Aug 9, 2019 | Jun 2019 | $-4.62 | $-4.20 | 9.09% |
| May 9, 2019 | Mar 2019 | $-6.16 | $-6.16 | - |
| Mar 18, 2019 | Dec 2018 | $-7.47 | $-8.68 | -16.20% |
| Nov 14, 2018 | Sep 2018 | $-8.03 | $-7.84 | 2.37% |
| Aug 9, 2018 | Jun 2018 | $-9.03 | $-8.12 | 10.08% |
| May 10, 2018 | Mar 2018 | $-7.77 | $-8.82 | -13.51% |
| Mar 13, 2018 | Dec 2017 | $-0.32 | $-0.46 | -43.75% |
| Nov 9, 2017 | Sep 2017 | $2.25 | $1.77 | -21.33% |
| Aug 10, 2017 | Jun 2017 | $-8.54 | $-7.42 | 13.11% |
| May 12, 2017 | Mar 2017 | $-0.71 | $-0.48 | 32.39% |
| Mar 31, 2017 | Dec 2016 | $-0.44 | $0.01 | 102.27% |
| Nov 18, 2016 | Sep 2016 | $-0.64 | $-0.79 | -23.44% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 24, 2022 | Dec 2021 | $-5.81 | $-6.09 | - |
| Mar 31, 2021 | Dec 2020 | $-4.56 | $-5.23 | - |
| Mar 25, 2020 | Dec 2019 | $-1.13 | $-14.98 | - |
| Mar 18, 2019 | Dec 2018 | $-2.30 | $-33.46 | - |
| Mar 13, 2018 | Dec 2017 | $0.43 | $-6.59 | - |
| Mar 31, 2017 | Dec 2016 | - | $-0.78 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 12, 2022 | Mar 2022 | $3.65M | $3.11M | 0.85% |
| Mar 24, 2022 | Dec 2021 | $3.40M | $-2.54M | - |
| Nov 12, 2021 | Sep 2021 | $3.65M | $3.10M | 0.85% |
| Aug 12, 2021 | Jun 2021 | $900.00K | $3.11M | 3.46% |
| May 11, 2021 | Mar 2021 | $2.42M | $2.42M | 1.00% |
| Mar 31, 2021 | Dec 2020 | $1.74M | $2.37M | 1.36% |
| Nov 10, 2020 | Sep 2020 | $560.00K | $1.46M | 2.61% |
| Aug 14, 2020 | Jun 2020 | $260.00K | $473.00K | 1.82% |
| May 13, 2020 | Mar 2020 | $5.17M | $9.03M | 1.75% |
| Mar 25, 2020 | Dec 2019 | $9.74M | $9.03M | 0.93% |
| Nov 7, 2019 | Sep 2019 | $9.00M | $9.01M | 1.00% |
| Aug 9, 2019 | Jun 2019 | $7.04M | $7.36M | 1.05% |
| May 9, 2019 | Mar 2019 | $6.77M | $7.02M | 1.04% |
| Mar 18, 2019 | Dec 2018 | $6.28M | $6.35M | 1.01% |
| Nov 14, 2018 | Sep 2018 | $6.93M | $5.82M | 0.84% |
| Aug 9, 2018 | Jun 2018 | $4.17M | $6.83M | 1.64% |
| May 10, 2018 | Mar 2018 | $3.37M | $4.07M | 1.21% |
| Mar 13, 2018 | Dec 2017 | $3.00M | $2.82M | 0.94% |
| Nov 9, 2017 | Sep 2017 | - | $6.17M | - |
| Aug 10, 2017 | Jun 2017 | - | $10.76M | - |
| May 12, 2017 | Mar 2017 | - | $7.41M | - |
| Mar 31, 2017 | Dec 2016 | - | $8.77M | - |
| Nov 18, 2016 | Sep 2016 | - | $9.40M | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 24, 2022 | Dec 2021 | $12.01M | $12.29M | 2.35% |
| Mar 31, 2021 | Dec 2020 | $3.68M | $4.31M | 17.09% |
| Mar 25, 2020 | Dec 2019 | $33.13M | $32.42M | -2.13% |
| Mar 18, 2019 | Dec 2018 | $23.00M | $23.07M | 0.29% |
| Mar 13, 2018 | Dec 2017 | $27.35M | $14.66M | -46.41% |
| Mar 31, 2017 | Dec 2016 | - | $36.43M | - |
APVO's next estimated earnings date (based on same quarter last year's report date) is Aug 12, 2022 for the fiscal quarter ending Jun 30, 2022.
Aptevo Therapeutics Inc's previous earnings date was May 12, 2022 for its fiscal quarter ended Mar 31, 2022.
APVO's earnings per share (EPS) was $-1.55, missing the consensus analysts forecast of $-1.15 by -34.78%.
The EPS was lower than the previous fiscal quarter (Dec 2021) by 22.05%, and higher than the same period a year before (Mar 2021) by -5.49%.
Revenues were $3.11M.
The company reported a net income of $-7.70M.Free cash flow for the quarter was $-5.12M , compared to $-4.00M last quarter and $-7.70M a year before.
APVO ended the quarter with $5.87M in total debt, a decrease of -54.88% compared to the previous quarter, and a decrease of -65.27% compared to the same quarter a year before.
Aptevo Therapeutics Inc's previous annual earnings date was Mar 24, 2022 for its fiscal year ended Dec 31, 2021.
APVO's earnings per share (EPS) was $-6.09, missing the consensus analysts forecast of $-5.81 by 4.82% , and lower than the previous year's EPS (Dec 2020) by 16.44%.
Revenues were $12.29M, better than the forecast of $12.01M by 2.35%, and up by 185.26% from previous year's revenue.
The company reported a net income of $-28.46M.
Aptevo Therapeutics Inc reported a free cash flow of $-22.39M for its fiscal year, compared to $-29.41M a year ago.
The company ended the fiscal year with $13.01M in total debt, an increase of 30.08% compared to the previous year.
